Hospital costs associated with adverse events in people with diabetes in the UK. Issue 11 (29th June 2022)

• Record Type: Journal Article
• Authors: Keng, Mi Jun; Leal, Jose; Bowman, Louise; Armitage, Jane; Mihaylova, Borislava
• Is Part Of: Diabetes, obesity & metabolism. Volume 24:Issue 11(2022)
• Page Start: 2108
• Page End: 2117
• Publication Date: 2022-06-29
• Subjects: cardiovascular disease -- cost‐effectiveness -- diabetes complications -- health economics; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.14796
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: Aim: To estimate the annual hospital costs associated with a range of adverse events for people with diabetes in the UK. Methods: Annual hospital costs (2019/2020) were derived from 15 436 ASCEND participants from 2005 to 2017 (120 420 person‐years). The annual hospital costs associated with cardiovascular events (myocardial infarction, coronary revascularization, transient ischaemic attack [TIA], ischaemic stroke, heart failure), bleeding (gastrointestinal [GI] bleed, intracranial haemorrhage, other major bleed), cancer (GI tract cancer, non‐GI tract cancer), end‐stage renal disease (ESRD), lower limb amputation and death (vascular, non‐vascular) were estimated using a generalized linear model following adjustment for participants' sociodemographic and clinical factors. Results: In the year of event, ESRD was associated with the largest increase in annual hospital cost (£20 954), followed by lower limb amputation (£17 887), intracranial haemorrhage (£12 080), GI tract cancer (£10 160), coronary revascularization (£8531 if urgent; £8302 if non‐urgent), heart failure (£8319), non‐GI tract cancer (£7409), ischaemic stroke (£7170), GI bleed (£5557), myocardial infarction (£4913), other major bleed (£3825) and TIA (£1523). In subsequent years, most adverse events were associated with lasting but smaller increases in hospital costs, except for ESRD, where the additional cost remained high (£20 090). Conclusions: Our study provides robust estimates of annual hospital costs associated with a range of adverse events in people with diabetes that can inform future cost‐effectiveness analyses of diabetes interventions. It also highlights the potential cost savings that could be derived from prevention of these costly complications.